Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Search BMS Clinical Trials
BMS Active Not Yet Recruiting Study icon

Active, Not Recruiting

Trial ID CA234-0001  |   NCT06764771

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Warning icon
Sorry, this study is no longer accepting new participants, but is still ongoing.
You may click the “Check Your Eligibility” button and answer a few questions about your health to find out if you might be a match to another study.
Check Your Eligibility

Summary

  • Phase 1
  • Male and Female Gender icon
  • 18+
    Age Range
  • BMS Active Not Yet Recruiting Study icon
    Active, Not Recruiting

Overview

This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.

print Print
email Email

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
:
  • Participant must be ≥ 18 years of age.
    1. Histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with any of the following tumor types:.
      1. Part 1A: clear-cell renal cell carcinoma (ccRCC), clear-cell ovarian cancer (ccOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).
        1. Parts 2A, 1D, 2D: ccRCC.
          1. Part 1B: solid tumors with KRAS G12C mutation.
            1. Part 2B: NSCLC with KRAS G12C mutation.
              1. Parts 1C, 2C: colorectal cancer (CRC) with KRAS G12C mutation.
              2. Participants must have an Eastern Cooperative Oncology Groups (ECOG) Performance Status of 0 or 1.
                1. Participants must have measurable disease per RECIST v1.1.

                  Exclusion Criteria

                  Exclusion Criteria Icon
                  :
                  • Untreated central nervous system (CNS) metastases.
                    1. Leptomeningeal metastasis (carcinomatous meningitis).
                      1. Impaired cardiac function or clinically significant cardiac disease.
                        1. For Parts 1B, 1C, 2B, 2C only (combination with adagrasib):.
                          1. History of pneumonitis or interstitial lung disease (ILD).
                            1. History of prior severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
                            2. Other protocol-defined inclusion/exclusion criteria apply.
                              Additional Information *

                              Treatment Options

                              Study Arms

                              ASSIGNED INTERVENTION

                              Study Arms

                              Experimental: Part 1A: BMS-986488 Monotherapy

                              ASSIGNED INTERVENTION
                              • Drug: BMS-986488

                              Study Arms

                              Experimental: Part 1B: BMS-986488 + Adagrasib

                              ASSIGNED INTERVENTION
                              • Drug: BMS-986488, Adagrasib

                              Study Arms

                              Experimental: Part 1C: BMS-986488 + Adagrasib + Cetuximab

                              ASSIGNED INTERVENTION
                              • Drug: BMS-986488, Adagrasib, Cetuximab

                              Study Arms

                              Experimental: Part 1D: BMS-986488 + Nivolumab

                              ASSIGNED INTERVENTION
                              • Drug: BMS-986488, Nivolumab

                              Study Arms

                              Experimental: Part 2A: BMS-986488 Monotherapy

                              ASSIGNED INTERVENTION
                              • Drug: BMS-986488

                              Study Arms

                              Experimental: Part 2B: BMS-986488 + Adagrasib

                              ASSIGNED INTERVENTION
                              • Drug: BMS-986488, Adagrasib

                              Study Arms

                              Experimental: Part 2C: BMS-986488 + Adagrasib + Cetuximab

                              ASSIGNED INTERVENTION
                              • Drug: BMS-986488, Adagrasib, Cetuximab

                              Study Arms

                              Experimental: Part 2D: BMS-986488 + Nivolumab

                              ASSIGNED INTERVENTION
                              • Drug: BMS-986488, Nivolumab

                              Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you